Product Introduction/Implementation Project Planning for Next-Generation PrEP
A Plan for Accelerating Access and Introduction of Injectable CAB for PrEP
AVAC’s Plan for Accelerating Access and Introduction of Injectable Cabotegravir (CAB) for PrEP provides a comprehensive view of all the moving parts involved in delivering this new PrEP option and identifies priorities for ensuring time is not wasted and opportunity is not squandered. The plan focuses on learning the lessons from the first ten years…
Long-Acting Injectable Cabotegravir: implementation science needed to advance this additional HIV prevention choice
In this article, the authors outline priority areas for implementation research needed to inform the effective scale-up of cabotegravir for PrEP.
Sustained Efficacy of Long-Acting Cabotegravir for PrEP Among Cisgender Women
This press release provides an overview of the new findings from HPTN 084, a trial of the HIV Prevention Trials Network studying injectable cabotegravir for PrEP among cisgender women. The updated results show reductions in HIV incidence were sustained in the 12 months following unblinding and were presented at the AIDS 2022 conference in Montreal.
WHO Guidelines on Long-Acting Injectable Cabotegravir for HIV Prevention
WHO guidelines, issued in 2022, recommend injectable cabotegravir (CAB) may be offered as an additional HIV prevention option for people at substantial risk of HIV infection. These guidelines provide considerations to support managers, policy makers, researchers, health workers, communities, and other stakeholders in the implementation of projects and programs for injectable CAB for PrEP. It…
AVAC, BMGF, CIFF, MedAccess, Unitaid and ViiV Healthcare announce collaboration to catalyse more affordable access to long- acting injectable cabotegravir for HIV prevention
AVAC press release announcing a new collaboration focused on pricing, innovative funding mechanisms, tracking regulatory approvals, and ensuring the inclusion of civil society in key planning and decision making to speed access to injectable cabotegravir (CAB) for PrEP. Launched at the 24th International AIDS Conference, this collaboration includes AVAC, the Bill and Melinda Gates Foundation,…
ViiV and Medicines Patent Pool Sign Voluntary Licensing Agreement for Cabotegravir for PrEP
ViiV Healthcare and the Medicines Patent Pool (MPP) announced the signing of a new voluntary licensing agreement for patents relating to cabotegravir for PrEP to help enable access in least developed, low-income, lower middle-income and Sub-Saharan African countries.